Reviewer's report

Title: Treatment of hyperprolactinemia: a systematic review and meta-analysis

Version: 3 Date: 4 May 2012

Reviewer: Fausto Bogazzi

Reviewer's report:

Wang et al. presented data of a systematic review and meta-analysis of different treatments of hyperprolactinemia. This was a huge work, rigorously performed. As expected, and in keeping with a large literature, dopamine agonists (DA) are affective, either on a clinical or biochemical ground, in the control oh hyperprolactinemia. Even more, the Authors provided evidence that DA are the treatment of choice in hyperprolactinemic patients; on the other hand, pituitary adenomectomy and external radiotherapy may have a role in patients refractory to medical therapy.

I have only minor suggestions for this ms, which is well written in a logical sequence:

1. Abstract: the conclusions are not fully supported by the data reported in the Results section of the Abstract;
2. The aim of the study should be better stated; in the abstract the Authors stated that “we aimed to compare efficacy and adverse effects of medications, surgery, and radiotherapy in the treatment of hyperprolactinemia” whereas at the end of introduction the Authors stated that they “evaluate the outcomes of treated hyperprolactinemia patients with regards to tumor growth and symptoms”.

Level of interest: An article of outstanding merit and interest in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I received unrestricted grants from Ipsen, Pfizer and Novartis.